Annuncio • May 26
Optimi Health Corp Advances Highest-Purity Natural Psilocybin Extract Optimi Health Corp. announced the completion of a production run of naturally derived psilocybin extract measuring approximately 6% psilocybin content, representing the highest-purity botanical psilocybin extract produced by the Company to date. The milestone reflects sustained gains across Optimi's cultivation program. Drawing on a proprietary library of more than 200 distinct mushroom genetics maintained at the Company's facilities, Optimi has selectively advanced cultivars demonstrating increasingly elevated psilocybin content. Those cultivation improvements, combined with refinements to the Company's extraction process, have produced a botanical extract substantially more concentrated than prior production cycles while maintaining its naturally derived profile. A portion of the completed extract has been earmarked to support upcoming clinical research programs in Europe, where Optimi is expected to supply GMP-grade finished material into sponsor-led studies. Consistent with the Company's role as a regulated manufacturer rather than a drug-development sponsor, Optimi's contribution is the supply of psilocybin-containing finished drug products. Remaining biomass from the psilocybin production cycle will be retained at Optimi's facilities for ongoing product development, formulation refinement, and future regulated supply initiatives as international access pathways continue to expand. The milestone also reinforces Optimi's commercial supply in Australia, where the Company's naturally derived 5 mg psilocybin capsules are being prescribed for treatment-resistant depression under the Therapeutic Goods Administration's Authorised Prescriber Scheme. The higher-purity extract strengthens the material base supporting that supply. Optimi remains among a small number of commercial-stage companies worldwide whose psilocybin drug products are reaching patients through reimbursed treatment pathways, with eligible Australian patients accessing psilocybin-assisted therapy for treatment-resistant depression supported by established reimbursement initiatives. Aggregated data published in connection with Australia's Authorised Prescriber Scheme, under which Optimi has supplied psilocybin finished products since September 2025, indicate that no serious adverse events have been reported among patients treated with psilocybin under the Scheme as of December 2025. New Risk • May 21
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 75% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (75% increase in shares outstanding). Revenue is less than US$1m (CA$194k revenue, or US$141k). Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (US$33.5m market cap). Board Change • May 21
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Independent Director Jason Mosberian was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Annuncio • May 20
Optimi Health Corp. has completed a Follow-on Equity Offering in the amount of $15 million. Optimi Health Corp. has completed a Follow-on Equity Offering in the amount of $15 million.
Security Name: Common Shares
Security Type: Common Stock
Securities Offered: 2,400,000
Price\Range: $6.25
Discount Per Security: $0.47
Transaction Features: New Market Listing Annuncio • Jan 27
Optimi Health Completes First 2026 Production of MDMA and Psilocybin Capsules Optimi Health Corp. reported that it has completed a production cycle for its MDMA and psilocybin capsules intended for supply into Australia under the Authorised Prescriber Scheme. The completed batch consists of 1,000 MDMA capsules in a 60 mg dosage form and 1,000 naturally derived psilocybin capsules in a 5 mg dosage form. Final packaging, labelling, and batch release were completed in accordance with Optimi's Drug Establishment Licence issued by Health Canada. The capsules are GMP-compliant and supported by Certificates of Analysis confirming conformance with applicable quality specifications, following receipt of the required Australian import permits. Post-Traumatic Stress Disorder (PTSD) and Treatment-Resistant Depression (TRD) represent significant unmet medical needs in Australia. National data published by the Australian Bureau of Statistics indicate that approximately 5-6% of Australians experience PTSD in a given year, representing roughly 1.3 to 1.5 million people. According to the Australian Institute of Health and Welfare, more than 1.3 million Australians are affected by depressive disorders, and clinical research suggests that around one-third of individuals with major depressive disorder do not respond adequately to standard treatments. Annuncio • Dec 20
Optimi Health Corp. Announces Board Changes Optimi Health Corp. has appointed Mr. Jason Mosberian as a director of the Company, effective 18 December 2025. Mr. Mosberian graduated from the Sauder School of Business and earned his CPA designation in 2011 working in audit in public practice for 6 years. He currently serves as Senior Vice President and Partner at BFL Canada and has over a decade of experience providing tailored risk management and insurance solutions to clients in various industries, including manufacturing, distribution and life sciences. Mr. Mosberian replaces Mr. Jonathan Schintler on the Company's Board of Directors. Mr. Mosberian's appointment is subject to the approval of the Canadian Securities Exchange. Annuncio • Sep 06
Optimi Health Corp. has filed an IPO in the amount of $27.0125 million. Optimi Health Corp. has filed an IPO in the amount of $27.0125 million.
Security Name: Common Shares
Security Type: Common Stock Annuncio • Jul 30
Optimi Health Corp., Annual General Meeting, Sep 08, 2025 Optimi Health Corp., Annual General Meeting, Sep 08, 2025. Location: unit 600, 21 water street, british columbia, v6b 1a1, vancouver Canada Annuncio • Jul 20
Optimi Health Corp. announced that it expects to receive CAD 3.45 million in funding Optimi Health Corp. announces a non-brokered private placement to issue 3,450 unsecured convertible debentures at a price of CAD 1,000 per Convertible Debenture for gross proceeds of CAD 3,450,000 on July 18, 2025. The Convertible Debentures will bear interest at a rate of 15% per annum. The principal amount of each Convertible Debenture will be convertible into common shares of the Company at a conversion price of CAD 0.15, being the closing price of the Common Shares on the Canadian Securities Exchange preceding the execution by each Investor of the subscription agreement for the Convertible Debentures. All securities issued under the Offering, including securities issuable on conversion thereof, will be subject to a hold period expiring four months and a day from the date of issuance, in accordance with the rules and policies of the CSE and applicable Canadian securities laws. The Offering is expected to close on or about July 24, 2025 Annuncio • Mar 12
Optimi Health Corp. announced a financing transaction Optimi Health Corp. announced a private placement that it will issue 100,000 common shares of the company at a deemed price per share to receive funding on March 12, 2025. The shares will be subject to a hold period of four months and one day from the date of issuance. Additionally, the Company is settling CAD 20,000 in outstanding service fees by issuing common shares at a deemed price per share equal to the closing price on the CSE on the last trading day prior to issuance. The transaction is expected to close on or around March 19, 2025. Annuncio • Feb 01
Optimi Health Corp. Completes Larger MDMA Capsule Batch to Date, Expands Stability Program Optimi Health Corp. has completed its larger production batch of MDMA to date—over 4,000 GMP capsules, enough to treat more than 1,000 patients. As part of its commitment to ensuring long-term product stability and quality, Optimi has also completed one year of stability data on previously manufactured MDMA capsules, validating a one-yearshelf life and extending the usability of its existing inventory for clinical and therapeutic applications. Additionally, the company has initiated a two-yearstability program to further validate the long-term quality and reliability of its MDMA capsules. With a growing number of authorized physicians prescribing Optimi's MDMA for PTSD in Australia, increasing demand for Special Access Program (SAP) requests in Canada, and a key Phase 2 clinical trial initiative for PTSD in Israel, Optimi is one of the few companies able to both manufacture its psychedelic drugs in-house and export cost-effective, GMP-grade MDMA capsules globally. Annuncio • Jan 31
Optimi Health Corp. Auditor Raises 'Going Concern' Doubt Optimi Health Corp. filed its Annual on Jan 29, 2025 for the period ending Sep 30, 2024. In this report its auditor, Davidson & Company, gave an unqualified opinion expressing doubt that the company can continue as a going concern. Annuncio • Jan 29
Optimi Health Corp. announced that it has received CAD 0.9735 million in funding On January 28, 2025. Optimi Health Corp has closed the transaction. it has issued 1,316,668 Units at a price of CAD 0.30 per unit for gross proceeds of CAD 395,000.14 in its second tranche. total Offering raise to CAD 934,000. Annuncio • Jan 16
Optimi Health Corp. Reports First Patients Dosed in Landmark Natural Psilocybin Study in New Zealand Optimi Health Corp. announced that its natural psilocybin extract has been successfully exported to New Zealand. The shipment has enabled the dosing of the first participants using Optimi's natural psilocybin extract in a groundbreaking clinical trial supported by Tu Wairua, and the Matai Medical Research Institute, based in Gisborne, New Zealand. The study is the first of its kind, combining indigenous Maori knowledge systems (matauranga Maori) with cutting-edge clinical methodologies to address methamphetamine addiction. The inaugural cohort of participants has completed preparatory sessions and received psilocybin-assisted therapy in a culturally grounded, marae-based setting using Optimi's natural p silocybin extract. Key Highlights. First Participants Dosed: Optimi's natural psilocbin extract was administered to participants at Rangiwaho Marae, marking a historic step in combining traditional healing frameworks with modern therapeutic approaches. Innovative Collaboration. The Tu Wairua initiative unites indigenous leaders, health researchers, and industry partners, including Rua Bioscience and the Institute of Environmental Science and Research (ESR), to explore the therapeutic potential of taonga (mushroom) varieties. Cultural Integration. The trial emphasizes tikanga (cultural protocols) and collective reflection to ensure the safety, feasibility, and long-term well-being of participants and their communities. Supporting Indigenous Leadership in Psychedelic Therapies. Building a Framework for Global Psychedelic Innovation. The study, supported by Rua Bioscience and other New Zealand-based organizations, is a testament to the global collaboration required to advance psychedelic medicine responsibly. Optimi's involvement underscores the Company's mission to make high-quality, natural psilocybin accessible to researchers and patients worldwide. Learnings from this clinical trial will inform future trial phases and contribute to the broader understanding of psilocybin-assisted therapies. Annuncio • Oct 24
Optimi Health Corp. Announces First PTSD Patients Treated with MDMA Capsules in Australia Optimi Health Corp. announced that the first group of patients with post-traumatic stress disorder (PTSD) in Australia has successfully received treatment with its GMP-certified MDMA capsules under the Authorised Prescriber Scheme. In response to growing demand, the Company has received an additional order for 700 doses after its initial shipment of 160 doses was fully allocated in under eight weeks. First Patient Dosing: Patients in Australia are being treated with Optimi's GMP-certifiedMD capsules for PTSD, positioning Optimi as one of the few companies with in-market products actively treating real patients. Additional Orders: An additional 700 doses of MDMA capsules have been ordered to meet demand after the initial 160 doses were fully allocated in less than eight weeks. Real World Data: The Patient Reported Outcomes (PROs) being gathered through the patient registry at Australian National University will provide data on the effectiveness of MDMA treatments across a diverse range of Australian patients. The data collected from thousands of patients using Optimi's MDMA will be one of the most comprehensive and valuable data sets in the history of psychedelic-assisted therapies. Optimi's close collaboration with Mind Medicine Australia-a leading non-profit focused on expanding access to psychedelic-assisted therapies-has been instrumental in bringing these treatments to market. Mind Medicine Australia advocates for the safe integration of psychedelics into mental health treatments and has been a key partner in connecting Optimi's MDMA with Australian healthcare providers. Annuncio • Oct 21
Optimi Health Corp. Announces Chief Executive Officer Changes Optimi Health Corp. announced that Mr. William (Bill) Ciprick will be stepping down as Chief Executive Officer due to personal reasons. Effective October 21, 2024, the Board has appointed Mr. Dane Stevens, Co-Founder of Optimi, as Interim Chief Executive Officer. In this role, Mr. Stevens will continue to advance the Company's key initiatives, with a focus on business development, expanding revenue opportunities, and maintaining the Company's strategic direction. Annuncio • Aug 08
Optimi Health Corp. announced that it expects to receive CAD 5 million in funding Optimi Health Corp. announced a non brokered private placement of up to 16,666,666 units at an issue price of CAD 0.30 per unit for the gross proceeds of CAD 4,999,999.8 on August 7, 2024. Each Unit comprised of one common share and one-half of one transferable Common Share purchase warrant. Each Warrant entitles the holder to acquire one Common Share at CAD 0.40 for two years from the date of issuance. It is anticipated that insiders of the Company may participate in the Offering for up to CAD 500,000. All securities issued under the Offering, including securities issuable on exercise thereof, will be subject to a hold period expiring 4 months and 1 day after issuance, in accordance with the rules and policies of the Exchange and applicable Canadian securities laws. In connection with the Offering the Company may pay, to qualified non-related parties, a finder’s fee in cash equal to 4% of the gross proceeds raised. Annuncio • May 15
Optimi Health Receives Certificate of Analysis for Mdma 40Mg and 60Mg Gmp Capsules Optimi Health Corp. announced it has received a Certificate of Analysis (COA) from independent third-party laboratory testing, confirming that Optimi’s formulated MDMA meets Good Manufacturing Practice (GMP) specifications. Optimi has also completed GMP process validation for the encapsulation of the active pharmaceutical ingredient (API) in both 40mg and 60mg dosage formats for batch sizes up to 1,000 capsules during GMP production. The COA for the finished product affirms important data and analytics around content uniformity, microbial and water content, and dosage strength. Additionally, Optimi’s ongoing stability testing demonstrated that the MDMA API used to make both dosages remains stable within the capsules under both real-time and accelerated storage conditions for up to three months. The MDMA API used to produce the releasable GMP capsules has a purity level of 99.95%. Annuncio • May 10
Optimi Health Corp. Receives Export Permit from Health Canada to Ship MDMA To Tel Aviv University's Institute for Psychedelic Research Optimi Health Corp. reported a significant update to its collaboration with The Institute for Psychedelic Research at Tel Aviv University (IPR-TLV). Optimi has obtained the Export Permit required from Health Canada for the shipment of its in-house manufactured MDMA active pharmaceutical ingredient (API) to IPR-TLV. With the Export Permit confirmed, Optimi will be one of the first psychedelics pharmaceutical manufacturers to ship MDMA to the country. Annuncio • Apr 16
Optimi Health Corp. Completes In-House Production of MDMA Active Pharmaceutical Ingredient Optimi Health Corp. has announced the completion of three batches of its MDMA Active Pharmaceutical Ingredient (API) manufactured from raw materials under the Company’s Precursor Licence. Optimi employed the precursor 3,4-Methylenedioxyphenyl-2-propanone (MDP2P) to guarantee the quality and uniformity of the MDMA API manufacturing process. The production of this MDMA API was produced in-house, explicitly for the recently disclosed supply agreement with the Institute for Psychedelic Research at Tel Aviv University (IPR-TLV) in Israel. Annuncio • Apr 02
Optimi Health Corp. Receives Finished Product Test Results and Certificate of Analysis for GMP Natural Psilocybin Extract Optimi Health Corp. announced that three validation batches of its Natural Psilocybin Extract have undergone full release testing and have been issued the Certificate of Analysis (COA) by a third-party, confirming compliance with Good Manufacturing Practice (GMP) specifications. Additionally, the Company has successfully completed the in-house encapsulation of psilocybin drug candidates in 5mg and 10mg dosage formats. The third-party COA confirms critical information regarding potency, water content, microbial content, and heavy metal content, ensuring that the Natural Psilocybin Extract meets the predetermined specifications. The completion of both extract validation and finished product testing aligns with Optimi's goal of advancing the drug candidate, marking significant progress toward its eventual release for human consumption. After six months of accelerated data collection, Optimi confirms that its Natural Psilocybin Extract maintained its original potency level without any degradation during stability testing. Furthermore, the Psilocybe cubensis mushrooms used in creating the extract were cultivated in-house under Good Agricultural Collection Practice (GACP) conditions. As the Company prepares to meet its Australian supply commitments with Mind Medicine Australia, Karina Lahnakoski, Optimi's Director of Quality and Commercial Strategies, assures patients and therapists of the reliability and quality of Optimi's drug candidates. Dedicated to fostering collaborations and advancing the scientific understanding of the potential therapeutic benefits of psilocybin, Optimi welcomes inquiries from principal investigators and research groups interested in learning more about the Company’s validated GMP Natural Psilocybin Extract and other drug candidates. Annuncio • Feb 10
Optimi Health Corp. announced that it expects to receive CAD 1.5 million in funding Optimi Health Corp announces non-brokered private placement of 5,000,000 units at an issue price of CAD 0.30 per Unit for gross proceeds of CAD 1,500,000 on February 8, 2024. Each unit consists of one common share and one half of one transferable Common Share purchase warrant. Each Warrant entitles the holder to acquire one (1) Common Share at CAD 0.40 for two (2) years from the date of issuance. the transaction include participation from insiders for CAD 605,000. All securities issued under the Offering, including securities issuable on exercise thereof, will be subject to a hold period expiring 4 months and 1 day after issuance, in accordance with the rules and policies of the Exchange and applicable Canadian securities laws. Annuncio • Dec 23
Optimi Health Corp., Annual General Meeting, Feb 22, 2024 Optimi Health Corp., Annual General Meeting, Feb 22, 2024. Annuncio • Nov 29
Optimi Health Corp. Achieves Genetics Milestone and Completes Psilocybin Extract Validation and Stability Testing Optimi Health Corp. has reached a significant milestone in its mission. The company is proud to announce the successful harvest of eight new natural Psilocybin genetics, strengthening its position as a pioneering force in the psychedelic research and formulation space. Demonstrating its commitment to innovation and research, Optimi has cultivated these new Psilocybin-containing mushroom strains with the aim that they will play a pivotal role in the development of psilocybin extracts and novel drug candidates. Optimi also announces the advancement of its full spectrum, GMP extract quality program. The Company has successfully completed process validation for the natural psilocybin drug candidate, and the stability testing according to ICH guidelines is ongoing. With over three months of accelerated data, Optimi can confirm the product is able to maintain potency and other quality attributes for the duration of clinical trials. While Optimi continues to develop its product offerings, it remains focused on fulfilling supply orders, conducting tests, and analyzing the recent milestone harvest. The company announced the availability of GMP Psilocybin API for encapsulation into standardized dosages or for sale to other groups as a raw material for their formulations. This marks a significant step in expanding the company's reach and impact within the psychedelic research community. Annuncio • Nov 08
Optimi Health Corp. Announces Executive Changes Optimi Health Corp. announced the appointment of Dr. Preston A. Chase as the Company’s Chief Science Officer (CSO). Dr. Chase is a distinguished Research & Development chemist and seasoned business professional with an impressive academic and industrial track record spanning over 25 years. His extensive experience includes pioneering the development and commercialization of innovative products and processes for both multinational corporations and startup ventures. He holds a BSc from the University of Victoria and a PhD from the University of Calgary, and a solid foundation in catalysis, synthesis, and analytical chemistry. With over 30 peer-reviewed scientific publications and numerous awarded and pending patents, he brings a wealth of research expertise and a strong history of commercial success to the Optimi Health team. In his new role, Dr. Chase will take charge of shaping and advancing research capabilities and delivering safe, effective products to the nascent psychedelic market. His mandate includes the critical task of establishing the scientific validity and utility of Optimi's GMP psilocybin and MDMA drug candidates while fostering transparent communication with scientific and customer communities. He will also lead a core scientific team throughout the development process, ensuring that the Company continues to push the boundaries of innovation. Further, his experience in analysis of botanicals for medical use will support the integrity of Optimi’s drug candidates and the robustness of the Company’s supply pathway, ensuring that Optimi meets the higher standards of quality assurance and regulatory compliance in cultivation and dose factor for its customers. As Dr. Chase assumes leadership of Optimi's R&D and science-driven protocols, the Company extends its appreciation to Justin Kirkland, the departing CSO, for his devoted service to Optimi during the last two years. Mr. Kirkland will continue his association with the Company as a project consultant. Annuncio • Sep 15
Optimi Health Corp. Announces Encouraging Results from the MAPS Phase 3 MDMA-Assisted Therapy Clinical Trial Optimi Health Corp. announced the positive and encouraging outcomes from the MAPS Phase 3 MDMA-Assisted Therapy (MDMA-AT) Clinical Trial published on Nature Medicine. The Company considers the results to be a substantial step forward in the treatment of individuals grappling with moderate to severe Post-Traumatic Stress Disorder (PTSD). The study, conducted across multiple sites, showcases the potential of MDMA-AT to significantly reduce PTSD symptoms and functional impairment, indicating it as a promising therapeutic avenue. The randomized, double-blind, confirmatory Phase 3 study focused on the assessment of the efficacy and safety of MDMA-assisted therapy in comparison to placebo with identical therapy. This trial was notably diverse, including a significant representation from the Hispanic/Latino community (26.9%) and individuals identifying as other than White (33.7%), presenting a comprehensive insight into the therapy's effectiveness across a broad spectrum of individuals. Moreover, the participants undergoing MDMA-AT displayed a marked improvement in functionality, as measured by the Sheehan Disability Scale (SDS) functional impairment score, with a mean change of -3.3 compared to -2.1 in the placebo group, also showcasing statistical significance with P=0.03 and a moderate effect size (d=0.4). An encouraging aspect of the trial outcomes is the general tolerability of the treatment. While seven participants experienced a severe treatment emergent adverse event (TEAE), there were no deaths or serious TEAEs reported, emphasizing the general safety of the MDMA-AT approach. Optimi gratefully acknowledges the participants, clinicians, and all involved who have played a crucial role in bringing this pioneering study to fruition. Annuncio • May 11
Natural Health Grants Optimi Health Corp. Product Site License by Health Canada Optimi Health Corp. announced the receipt of its Natural Health Product Site License following an assessment by the Natural and Non-prescription Health Products Directorate. Under section 29 of the Natural Health Products Regulations, the expanded licensing allows for the manufacturing, packaging, and labelling of Natural Health Products (“NHPs”) at the Company’s Princeton, British Columbia facility. Further, the license also gives Optimi the ability to encapsulate products on site. Announcement affirms Optimi’s commitment to supplying large scale research and development programs through its 10,000 square foot GMP compliant manufacturing facility. Annuncio • Feb 08
Optimi Health Submits Phase I Clinical Trial Application Combining The Use Of Proprietary Psilocybin and MDMA Drug Candidates In Healthy Therapists Optimi Health Corp. announced the submission of its clinical trial application (CTA) for a Phase I combinatorial study that will document the safety of Optimi’s natural psilocybin standardized extract and proprietary 3,4-methylenedioxy-methamphetamine (MDMA) drug candidate in healthy therapist subjects. Optimi announced the successful completion of its novel MDMA drug candidate, OPTI-MHCL, which was tested for purity on-site with a result of >99% over multiple consistent batches by Chief Science Officer, Justin Kirkland. Both drug candidates are scheduled to be administered in the clinical trial and will be manufactured in-house at Optimi’s 20,000 square foot facilities in Princeton, British Columbia. The investigator-initiated double-blind placebo-controlled study is being conducted through ATMA Journey Centers in Calgary, Alberta, and will be the first-of-its-kind to directly compare the acute effects of these substances within the same clinical study. ATMA is currently the only Canadian organization that has completed a successful Phase I safety trial with natural psilocybin in healthy therapists. The primary objective of the trial is to demonstrate the safety and tolerability of the combinatory use of natural psilocybin and MDMA in healthy participants, broadly validating Optimi’s offering and, in later stages, indicating the suitability for use of these substances, combined and separately, in experiential training by psychedelic therapy practitioners. Annuncio • Feb 07
Optimi Health Completes First Production of Novel MDMA Drug Candidate OPTI-MHCL Optimi Health Corp. announced the completion of its proprietary preclinical MDMA drug candidate OPTI-MHCL for use in drug development, clinical trials, and individual patients authorized by Health Canada’s Special Access Program and Australia’s recently announced Authorized Prescriber Scheme. The production of OPTI-MHCL was made using the Company’s proprietary method and makes Optimi the only publicly listed psychedelics company licensed by Health Canada to possess, produce, assemble, sell, and supply its formulation in patient-ready encapsulated doses across global markets. OPTI-MHCL was manufactured in accordance with GMP protocols led by Chief Science Officer, Justin Kirkland, at the Company’s lab in Princeton, British Columbia and was validated after Kirkland achieved consistent results over multiple batches. In addition to on-site testing, Optimi submits all of its products to third-party laboratories for independent analysis to ensure the highest possible purity and suitability for OPTI-MHCL’s anticipated universal use. On September 22, 2022, Optimi and ATMA Journey Centers announced their intent to proceed with a Phase I clinical trial application (CTA) using Optimi’s natural psilocybin extract and MDMA. The goal of the trial is to support a pathway towards regulatory approval by establishing the safety and tolerability of both drug candidates on healthy patients. Optimi Health products are still being investigated through a clinically validated development program for the purpose of applying for market authorization. Annuncio • Jan 12
Optimi Health Corp. Announces Departs Michael Stier as Director Optimi Health Corp. announced that departing of Mr. Michael Stier as director following the Company's Annual General Meeting held January 9, 2023. Annuncio • Nov 12
Optimi Health Corp., Annual General Meeting, Jan 09, 2023 Optimi Health Corp., Annual General Meeting, Jan 09, 2023. 